The correlation between vascular endothelial growth factor and prostate cancer with and without metabolic syndrome

Authors

  • Ya-nan Zhou Department of Urology, Affiliated Hospital of ChengDe Medical University, Chengde, PR China
  • Jin-qi Song Department of Urology, Affiliated Hospital of ChengDe Medical University, Chengde, PR China
  • Gang-liang Tu Department of Urology, Affiliated Hospital of ChengDe Medical University, Chengde, PR China
  • Hui Xu Department of Urology, Affiliated Hospital of ChengDe Medical University, Chengde, PR China
  • Meng Ding Department of Clinical Laboratory, Affiliated Hospital of ChengDe Medical University, Chengde, PR China

DOI:

https://doi.org/10.3126/njc.v5i1.41410

Keywords:

metabolic syndrome, metabolic components, vascular endothelial growth factor, prostate cancer, Gleason score

Abstract

Objective: To investigate the relationship between vascular endothelial growth factor (VEGF), metabolic syndrome and its components and degree of differentiation of prostate cancer. 

Methods: The clinical data of 49 PCa cases treated during October, 2018 to February, 2021 were retrospectively analyzed, including patients’ height, weight, body mass index (BMI), age, blood pressure (BP), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), vascular endothelial growth factor (VEGF) and Gleason score. 

Results: Compared with simple PCa group, BMI, the MS group had higher BMI, diastolic blood pressure (DBP, FGB, TG) and VEGF (P<0.05), and higher Gleason score (P<0.05). MS group had a higher degree of malignancy (Gleason≥8). 

Conclusion: This suggests that MS may promote the progression of PCa, and the increase of VEGF level can indicate the presence of MS in PCa patients, reflecting the progression of PCa to a certain extent. 

Downloads

Download data is not yet available.
Abstract
64
PDF
66

Downloads

Published

2021-09-26

How to Cite

Zhou, Y.- nan, Song, J.- qi, Tu, G.- liang, Xu, H., & Ding, M. (2021). The correlation between vascular endothelial growth factor and prostate cancer with and without metabolic syndrome. Nepalese Journal of Cancer, 5(1), 19–23. https://doi.org/10.3126/njc.v5i1.41410

Issue

Vol. 5 No. 1 (2021)

Section

Original Articles

License

Copyright (c) 2021 Nepalese Journal of Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as NJC and the authors are acknowledged.

Submission of the manuscript means that the authors agree to assign exclusive copyright to NJC. The aim of NJC is to increase the visibility and ease of use of open access scientific and scholarly articles thereby promoting their increased usage and impact.